Akèy › Pwoteyinuri
Etid klinik pou Pwoteyinuri ap rekrite nan Etazini
17 etid pou Pwoteyinuri ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Aurora, CO5 etid
- Houston, TX5 etid
- Miami, FL4 etid
- Cedar Rapids, IA3 etid
- Washington, DC3 etid
- Los Angeles, CA3 etid
- Boston, MA3 etid
- Philadelphia, PA3 etid
- Salt Lake City, UT3 etid
- Orlando, FL3 etid
Pa eta
- Colorado8 etid
- Florid8 etid
- Georgia4 etid
- Iowa3 etid
- Kalifòni6 etid
- Maryland3 etid
- Massachusetts4 etid
- Michigan3 etid
- Ohio3 etid
- Pennsylvania5 etid
- Texas5 etid
- Utah3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Ap rekriteFaz 2
Laj 18 a 115 · Tout sèks · Mizajou Sep 30, 2026 · NCT06664814A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Sep 25, 2026 · NCT07541287Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Ap rekriteFaz 2
Laj 18 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT00977977Urinary Vitamin C Loss in Diabetic Subjects
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 22, 2026 · NCT00071526Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Ap rekriteFaz 3
Laj 2 a 18 · Tout sèks · Mizajou Sep 9, 2026 · NCT06994845A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07268638A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Aug 10, 2026 · NCT07146906Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Jul 30, 2026 · NCT05268289Study of Ravulizumab in Pediatric Participants With Primary IgAN
Ap rekriteFaz 3
Laj 2 a 18 · Tout sèks · Mizajou Jul 30, 2026 · NCT07024563Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07224776Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Ap rekriteFaz 3
Laj 12 a 60 · Tout sèks · Mizajou Jul 13, 2026 · NCT04817618Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Ap rekriteFaz 3
Laj 12 a 60 · Tout sèks · Mizajou Jul 13, 2026 · NCT05755386Study of BHV-1400 in IgA Nephropathy
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jun 23, 2026 · NCT07054684Empagliflozin Treatment in Kidney Transplant Recipients
Ap rekriteFaz 4
Laj 19 ak plis · Tout sèks · Mizajou Apr 21, 2026 · NCT06013865Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 7 a 18 · Tout sèks · Mizajou Dec 11, 2025 · NCT04752293Proteinuria in Pre and Post Transplant
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Nov 21, 2025 · NCT01094327Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Oct 4, 2024 · NCT01016613Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.